Scarica l'app Stockscreener
87.36
0.78%
0.68
Dopo l'orario di chiusura:
87.35
-0.01
-0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$86.68
Aprire:
$86.96
Volume 24 ore:
5.54M
Relative Volume:
1.10
Capitalizzazione di mercato:
$50.30B
Reddito:
$6.30B
Utile/perdita netta:
$1.07B
Rapporto P/E:
47.46
EPS:
1.8406
Flusso di cassa netto:
$1.09B
1 W Prestazione:
+1.87%
1M Prestazione:
+6.03%
6M Prestazione:
+3.02%
1 anno Prestazione:
+18.09%
Intervallo 1D:
$86.52
$87.83
Intervallo di 1 settimana:
$83.17
$89.60
Portata 52W:
$72.30
$89.60
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
87.36 | 49.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
88.41 | 154.15B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 115.45B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 100.32B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 66.81B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-01 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-12-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-10-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
Edwards Lifesciences StockCEO executes small preset share sale - AD HOC NEWS
Edwards Lifesciences Corp (EW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Edwards Lifesciences Corp (EW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Edwards Lifesciences CEO Zovighian sells $45,982 of stock - Investing.com
Edwards Lifesciences (EW) CEO sells 523 shares under Rule 10b5-1 plan - Stock Titan
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Lifesciences Corp (EW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Edwards Lifesciences (EW) Hits 52-Week High on Medicare Coverage Proposal - GuruFocus
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences (EW) Sees Positive Coverage Update Boosting Stock Prospects - GuruFocus
Edwards Lifesciences (EW) Gains Analyst Support Amid Coverage Up - GuruFocus
Edwards Lifesciences (EW) Set to Gain from Medicare Coverage Exp - GuruFocus
Edwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve Device - Benzinga
Edwards Lifesciences jumps as CMS posts proposed TAVR coverage update - Quiver Quantitative
Is Edwards Lifesciences Ready For Its Next Growth Phase? - Kalkine Media
Edwards Lifesciences (EW) Sees 3% Rise Following CMS Coverage An - GuruFocus
Edwards Lifesciences stock hits 52-week high at $89.50 - Investing.com
Edwards Lifesciences (EW) Sees Gains Following CMS Coverage Prop - GuruFocus
Why is Edwards Lifesciences stock climbing today? - Investing.com
Edwards Lifesciences stock jumps on TAVR coverage proposal - Investing.com
Leerink reiterates Edwards Lifesciences stock rating on TAVR policy - Investing.com
Leerink reiterates Edwards Lifesciences stock rating on TAVR policy By Investing.com - Investing.com UK
Edwards Lifesciences Corp. stock rises Monday, still underperforms market - MarketWatch
Edwards Lifesciences Stock (US28176E1082): Valuation Metrics Under the Microscope - AD HOC NEWS
Is Edwards Lifesciences stock underperforming the Nasdaq? - MSN
Sector Gamma AS Acquires 23,422 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Parnassus Investments LLC Acquires 111,843 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Stock Watched As Procedure Recovery Matters - Kalkine Media
Deutsche Bank AG Has $475.59 Million Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
CIBC Asset Management Inc Grows Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
Edwards Lifesciences (NYSE:EW) Hits New 1-Year HighTime to Buy? - MarketBeat
Edwards Tricuspid Valve Gets FDA OK - Orange County Business Journal
Possible Bearish Signals With Edwards Lifesciences Insiders Disposing Stock - Yahoo Finance
Edwards Lifesciences Corp. Hits New 52-Week High at $89.14 - MarketsMojo
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Edwards Holds Annual Patient Experience Day - Orange County Business Journal
Is Edwards Lifesciences Stock Underperforming the Nasdaq? - Barchart
TD Cowen Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $104 - Moomoo
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Bank of New York Mellon Corp Sells 1,517,638 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
TD Cowen raises Edwards Lifesciences stock price target on TAVR market share gains - Investing.com
Nomura Asset Management Co. Ltd. Has $36.83 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences (EW) CFO Theodora Mistras files initial Form 3 report - Stock Titan
Intech Investment Management LLC Has $5.91 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Insider Sell: Andrew Dahl Sells Shares of Edwards Lifesciences C - GuruFocus
Geode Capital Management LLC Trims Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Andrew Dahl Sells 568 Shares of Edwards Lifesciences (NYSE:EW) Stock - MarketBeat
Edwards Lifesciences (EW) SVP records small open-market stock sale - Stock Titan
Edwards Lifesciences (NYSE: EW) affiliate reports two 13,000-share sales - Stock Titan
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):